On December 12, Deutsche Bank analyst Neena Bitritto-Garg initiated coverage of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) shares with a 'Buy' rating and a price target of $36 which represents a potential upside of 148.28% based on the share price on December 22.